Generic Name and Formulations:
Methscopolamine bromide 2.5mg; tabs; lactose-free.
Indications for PAMINE:
Adjunctive therapy in peptic ulcer.
Initially 2.5mg 30min before meals and 2.5–5mg at bedtime; may increase as tolerated. Severe symptoms: may start at 5mg 30min before meals and at bedtime.
Glaucoma. Obstructive uropathy (eg, bladder neck obstruction due to prostatic hypertrophy). GI obstruction (eg, pyloroduodenal stenosis). Paralytic ileus. Intestinal atony in elderly or debilitated. Unstable cardiovascular status in acute hemorrhage. Severe ulcerative colitis. Toxic megacolon complicating ulcerative colitis. Myasthenia gravis.
Ileostomy or colostomy. Autonomic neuropathy. Hepatic or renal disease. Ulcerative colitis. Hyperthyroidism. Coronary heart disease. CHF. Tachyrhythmia. Tachycardia. Hypertension. Prostatic hypertrophy. Large doses may suppress intestinal motility or aggravate toxic megacolon. Follow-up with upper GI contrast radiology or endoscopy during treatment. Obtain stool tests, hemoglobin, and hematocrit to rule out ulcer bleeding. High environmental temperature. Elderly. Pregnancy (Cat.C). Nursing mothers.
Additive anticholinergic effects with concomitant antipsychotics, tricyclic antidepressants, and other anticholinergic drugs. Concomitant antacids may interfere with absorption.
Tachycardia, palpitation, anaphylaxis, headache, nervousness, drowsiness, dizziness, blurred vision, pupil dilation, loss of taste, urinary hesitancy/retention, nausea, vomiting, constipation, decreased sweating, urticaria, xerostomia, weakness, insomnia, impotence, lactation suppression.
Tabs—100; Forte—60 (5x12 blisters)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib